HLSQNYSEServices-Prepackaged SoftwareFiscal year ends December 31
Tessera Defense & Homeland Security Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.22+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $2.30M
- P/E (TTM)
- 0.0
- Dividend yield
- –
Ownership
Who owns Tessera Defense & Homeland Security's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 4 sales
Net sold $8.25M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Deerfield Management Company, L.P. | 889,928 | 8.09% | 13D (active) amendment | May 26, 2026 |
| POD Sarl | 82,618 | 5.20% | 13G (passive) amendment | Mar 31, 2026 |
| Nantahala Capital Management, LLC | 730,551 | 7.13% | 13G (passive) amendment | Jun 30, 2026 |
| Gur Aryeh Segal | 553,800 | 9.99% | 13G (passive) | Apr 13, 2026 |
| Ram Naim | 477,600 | 5.30% | 13D (active) amendment | Sep 30, 2026 |
| Pyu Pyu Capital, LLC | 381,422 | 19.99% | 13D (active) | Dec 26, 2025 |
| Wilmot B. Harkey | 2,494,197 | 9.99% | 13G (passive) amendment | Mar 31, 2025 |
| Geneva Holding Company (GHC) SA | 1,970,403 | 7.60% | 13G (passive) | Apr 21, 2025 |
| Morgan Stanley & Co. LLC | 1,854,032 | 7.10% | 13G (passive) | Jun 30, 2025 |
| Menachem Shalom | 1,600,000 | 20.40% | 13D (active) amendment | Apr 10, 2026 |
| Daniel Mack | 156,696 | 9.99% | 13G (passive) amendment | Dec 31, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jonathan Eitan Solomon | Chief Executive Officer, Director | 126,748 | 0.47% | Apr 21, 2025 |
| Merav Bassan | Chief Development Officer | 79,597 | 0.30% | Apr 21, 2025 |
| Marina Wolfson | Chief Financial Officer | 68,545 | 0.26% | Apr 21, 2025 |
| Reuven Yeganeh | Director, 10% owner | 0 | – | Mar 18, 2026 |
| Liat Cohavi Bidas | Director | – | – | Mar 3, 2026 |
| James E. Flynn | Director | – | – | Apr 23, 2025 |
| Deerfield Healthcare Innovations Fund II, L.P. | Director | – | – | Apr 23, 2025 |
| Deerfield Mgmt V, L.P. | Director | – | – | Apr 23, 2025 |
| Deerfield Private Design Fund V, L.P. | Director | – | – | Apr 23, 2025 |
| Deerfield Mgmt HIF, L.P. | Director | 17,876,098 | 66.89% | Apr 23, 2025 |
| Deerfield Management Company, L.P. | Director | 2,494,108 | 9.33% | Apr 23, 2025 |
| Russell Greig | Director | 3,750 | 0.01% | Apr 21, 2025 |
| Jonathan S. Leff | Director | – | – | Apr 21, 2025 |
| Eddie Williams | Director | – | – | Apr 21, 2025 |
| Jesse Goodman | Director | – | – | Apr 21, 2025 |
| Susan Blum | Director | – | – | Apr 21, 2025 |
| Alan Charles Moses | Director | 5,000 | 0.02% | Apr 21, 2025 |
| Gregory Louis Merril | Director | – | – | Apr 21, 2025 |
| Fibrosis Foundation Cystic | 10% owner | 1,787,758 | 6.69% | Mar 4, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Reuven Yeganeh Director, 10% owner | Mar 17, 2026 | Sale | −530,000 | $5.00 | $2.65M | 0 |
| Reuven Yeganeh Director, 10% owner | Mar 17, 2026 | Conversion | +530,000 | $2.00 | $1.06M | 530,000 |
| Reuven Yeganeh Director, 10% owner | Mar 16, 2026 | Conversion | +450,000 | $2.00 | $900.00K | 450,000 |
| Reuven Yeganeh Director, 10% owner | Mar 16, 2026 | Sale | −450,000 | $5.00 | $2.25M | 0 |
| Reuven Yeganeh Director, 10% owner | Mar 13, 2026 | Conversion | +370,000 | $2.00 | $740.00K | 370,000 |
| Reuven Yeganeh Director, 10% owner | Mar 13, 2026 | Sale | −370,000 | $5.00 | $1.85M | 0 |
| Reuven Yeganeh Director, 10% owner | Mar 12, 2026 | Sale | −300,000 | $5.00 | $1.50M | 0 |
| Reuven Yeganeh Director, 10% owner | Mar 11, 2026 | Conversion | +300,000 | $2.00 | $600.00K | 30,000 |
| Marina Wolfson Chief Financial Officer | Apr 14, 2025 | Award | +68,545 | – | – | 68,545 |
| Merav Bassan Chief Development Officer | Apr 14, 2025 | Award | +79,597 | – | – | 79,597 |
| Jonathan Eitan Solomon Chief Executive Officer, Director | Apr 14, 2025 | Award | +126,748 | – | – | 126,748 |
| Jonathan Eitan Solomon Chief Executive Officer, Director | Apr 14, 2025 | Award | +126,748 | – | – | 126,748 |
| Marina Wolfson Chief Financial Officer | Apr 14, 2025 | Award | +68,545 | – | – | 68,545 |
| Merav Bassan Chief Development Officer | Apr 14, 2025 | Award | +79,597 | – | – | 79,597 |
| Deerfield Management Company, L.P. Director | Feb 27, 2025 | Option exercise | +353,249 | $0.93 | $328.52K | 1,247,054 |
| Deerfield Management Company, L.P. Director | Feb 27, 2025 | Option exercise | +353,249 | $0.93 | $328.52K | 1,247,054 |
| Jonathan Eitan Solomon Chief Executive Officer, Director | Sep 16, 2024 | Award | +50,556 | – | – | 53,056 |
| Merav Bassan Chief Development Officer | Sep 16, 2024 | Award | +31,749 | – | – | 31,749 |
| Assaf Oron Chief Business Officer | Sep 16, 2024 | Award | +25,804 | – | – | 25,804 |
| Fibrosis Foundation Cystic 10% owner | Jul 15, 2024 | Conversion | +854,700 | – | – | 1,787,758 |
| Deerfield Mgmt HIF, L.P. Director | Jul 15, 2024 | Option exercise | +5,883,000 | – | – | 8,938,049 |
| Deerfield Mgmt HIF, L.P. Director | Jul 15, 2024 | Option exercise | +5,883,000 | – | – | 8,938,049 |
| Carl L. Gordon 10% owner | May 15, 2024 | Option exercise | +9,280,408 | $0.24 | $2.23M | 13,797,997 |
| Carl L. Gordon 10% owner | May 15, 2024 | Sale | −24,344 | $0.38 | $9.25K | 13,773,653 |
| Fibrosis Foundation Cystic 10% owner | May 15, 2024 | Option exercise | +4,778,265 | – | – | 9,330,580 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Mar 15, 2024 | Award | +3,055,049 | – | – | 3,055,049 |
| Deerfield Mgmt HIF, L.P. Director, 10% owner | Mar 15, 2024 | Award | +3,055,049 | – | – | 3,055,049 |
| Assaf Oron Chief Business Officer | Nov 29, 2023 | Sale | −2,056 | $0.34 | $699 | 0 |
| Assaf Oron Chief Business Officer | Nov 29, 2023 | Sale | −3,414 | $0.35 | $1.19K | 2,056 |
| Assaf Oron Chief Business Officer | Nov 29, 2023 | Sale | −5,444 | $0.40 | $2.18K | 5,470 |
| Assaf Oron Chief Business Officer | May 22, 2023 | Buy | +3,192 | $0.27 | $862 | 10,914 |
| Assaf Oron Chief Business Officer | May 19, 2023 | Buy | +6,521 | $0.28 | $1.83K | 7,722 |
| Assaf Oron Chief Business Officer | May 18, 2023 | Buy | +1,201 | $0.27 | $324 | 1,201 |
| Israel GP Ltd. OrbiMed 10% owner | Feb 27, 2023 | Buy | +348,000 | $0.25 | $87.00K | 3,161,489 |
| Chidozie Ugwumba – | Nov 4, 2022 | Sale | −1,501 | $0.38 | $570 | 2,997,025 |
| Chidozie Ugwumba – | Nov 3, 2022 | Sale | −2,000 | $0.37 | $740 | 2,998,526 |
| Chidozie Ugwumba – | Nov 2, 2022 | Sale | −2,416 | $0.36 | $870 | 3,000,526 |
| Chidozie Ugwumba – | Nov 1, 2022 | Sale | −1,300 | $0.36 | $468 | 3,002,942 |
| Chidozie Ugwumba – | Oct 31, 2022 | Sale | −3,300 | $0.37 | $1.22K | 3,004,242 |
| Chidozie Ugwumba – | Oct 28, 2022 | Sale | −1,526 | $0.36 | $549 | 3,007,542 |
| Chidozie Ugwumba – | Oct 27, 2022 | Sale | −1,505 | $0.36 | $542 | 3,009,068 |
| Chidozie Ugwumba – | Oct 26, 2022 | Sale | −12,500 | $0.35 | $4.38K | 3,010,573 |
| Chidozie Ugwumba – | Oct 25, 2022 | Sale | −3,072 | $0.37 | $1.14K | 3,023,073 |
| Chidozie Ugwumba – | Oct 24, 2022 | Sale | −5,900 | $0.35 | $2.07K | 3,026,145 |
| Chidozie Ugwumba – | Oct 21, 2022 | Sale | −5,400 | $0.37 | $2.00K | 3,032,045 |
| Chidozie Ugwumba – | Oct 20, 2022 | Sale | −6,636 | $0.37 | $2.46K | 3,037,445 |
| Chidozie Ugwumba – | Oct 19, 2022 | Sale | −4,501 | $0.37 | $1.67K | 3,044,081 |
| Chidozie Ugwumba – | Oct 18, 2022 | Sale | −15,300 | $0.35 | $5.36K | 3,048,582 |
| Chidozie Ugwumba – | Oct 17, 2022 | Sale | −8,098 | $0.34 | $2.75K | 3,063,882 |
| Chidozie Ugwumba – | Oct 14, 2022 | Sale | −3,420 | $0.33 | $1.13K | 3,071,980 |
| Chidozie Ugwumba – | Oct 13, 2022 | Sale | −11,314 | $0.33 | $3.73K | 3,075,400 |
| Chidozie Ugwumba – | Oct 12, 2022 | Sale | −9,700 | $0.33 | $3.20K | 3,086,714 |
| Chidozie Ugwumba – | Oct 11, 2022 | Sale | −5,988 | $0.33 | $1.98K | 3,096,414 |
| Chidozie Ugwumba – | Oct 10, 2022 | Sale | −10,043 | $0.33 | $3.31K | 3,102,402 |
| Chidozie Ugwumba – | Oct 7, 2022 | Sale | −24,708 | $0.36 | $8.89K | 3,112,445 |
| Chidozie Ugwumba – | Oct 6, 2022 | Sale | −25,098 | $0.44 | $11.04K | 3,137,153 |
| Chidozie Ugwumba – | Oct 5, 2022 | Sale | −46,785 | $0.44 | $20.59K | 3,162,251 |
| Chidozie Ugwumba – | Oct 4, 2022 | Sale | −19,200 | $0.34 | $6.53K | 3,209,036 |
| Chidozie Ugwumba – | Oct 3, 2022 | Sale | −15,022 | $0.33 | $4.96K | 3,228,236 |
| Chidozie Ugwumba – | Sep 30, 2022 | Sale | −8,662 | $0.36 | $3.12K | 3,243,258 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.